Kairos Pharma, Ltd. (KAPA) Stock Price & Analysis
Kairos Pharma, Ltd. (KAPA) fell 4.33% to USD 0.29 as of July 25, 2026 at 03:41 UTC, according to Nexqual real-time market data.
KAPA last closed at USD 0.3; the session ranged USD 0.28–0.32 on volume of 1,460,223 shares. Market capitalization is $6.10M, with a 52-week range of USD 0.27–2.11 (ASE). Source: Nexqual, July 25, 2026 at 03:41 UTC.
Key Statistics (as of July 25, 2026 at 03:41 UTC)
| Price | USD 0.29 |
|---|---|
| Change | ▼ 4.33% (down) |
| Previous Close | USD 0.3 |
| Open | USD 0.3 |
| Day Range | USD 0.28 – 0.32 |
| 52-Week Range | USD 0.27 – 2.11 |
| Volume | 1,460,223 shares |
| Market Cap | $6.10M |
| Exchange | ASE |
Technical Analysis (KAPA)
Nexqual's technical model rates KAPA "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:41 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.56 (neutral) |
| vs SMA50 | Below (USD 0.42) |
| MACD | -0.03 (negative) |
Analyst Ratings (KAPA)
Wall Street analysts rate KAPA "Strong Buy" based on 2 analysts, with a mean price target of USD 7 (range USD 2–12), per Nexqual as of July 25, 2026 at 03:41 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 7 |
| High Target | USD 12 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (KAPA)
| EPS Estimate | USD -0.09 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.07 ▼ miss |
| 2025-12-31 | USD -0.07 vs est 0.03 ▼ miss |
| 2025-09-30 | USD -0.07 vs est -0.08 ▲ beat |
| 2025-06-30 | USD -0.08 vs est -0.05 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
Financials & Fundamentals (KAPA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -93.84% |
| Current Ratio | 10.31 |
| Total Cash | $3.67M |
| Total Debt | $0 |
| Free Cash Flow | $-1.63M |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
Financial Health Score (KAPA)
Nexqual rates Kairos Pharma, Ltd.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:41 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $4M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$4M |
| Efficiency | Critical — ROE -94%, ROA -54.8% |
Ownership (KAPA)
| Insider Ownership | +37.20% |
|---|---|
| Institutional Ownership | +6.94% |
| Shares Outstanding | 21.41M |
| Float | 13.42M |
| Short % of Float | +1.07% |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
Leadership (KAPA)
Kairos Pharma, Ltd. is led by John S. Yu (age 61), CEO, Chairman & Secretary, per Nexqual as of July 25, 2026 at 03:41 UTC.
| CEO, Chairman & Secretary | John S. Yu (age 61) |
|---|---|
| Chief Financial Officer | Douglas W. Samuelson (age 65) |
| Chief Scientific Officer | Neil A. Bhowmick (age 54) |
| Vice President of Research & Development | Ramachandran Murali (age 65) |
Major Backers & Investors (KAPA)
Notable institutional backers of Kairos Pharma, Ltd. include Fidelity, Two Sigma Investments, LP, SevenBridge Financial Group, LLC, according to Nexqual as of July 25, 2026 at 03:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.42% |
| Two Sigma Investments, LP | 0.26% |
| SevenBridge Financial Group, LLC | 0.21% |
| Aptus Capital Advisors, LLC | 0.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.47% |
| Geode Capital | 0.52% |
| State Street | 0.11% |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
From Kairos Pharma, Ltd.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer.
- The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
- It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SLXN | Silexion Therapeutics Corp | USD 2.27 | ▼ 9.92% |
| PLRZ | Polyrizon Ltd. | USD 14.68 | ▲ 2.02% |
| AZTR | Azitra Inc | USD 0.13 | ▼ 3.08% |
| GCTK | GlucoTrack, Inc. | USD 0.29 | ▼ 4.84% |
| NIVF | NewGenIvf Group Limited | USD 1.1 | ▼ 13.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:41 UTC. This page is informational and not investment advice.